Marina Biotech (MRNA) Posts Wider than Expected Q1 Loss
Tweet
Share
E-mailGet Alerts MRNA Hot Sheet
Join SI Premium – FREE
Marina Biotech, Inc. (Nasdaq: MRNA) reported Q1 loss of ($0.12), $0.01 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $214 million versus the consensus estimate of $150 thousand.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Moderna (MRNA) Following FDA Approval of mRNA Flu Vaccine
- Trump Administration Weighs Order On Autism And Vaccines - Bloomberg
- Atossa Genetics (ATOS) Tops Q2 EPS by 10c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
